Cytosorbents

CTSO · NASDAQ

$5.32+$0.36 (+7.26%)TodayMarket closed · Oct 20, 7:47 PM ET

Prev close $4.96

CTSO analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy1
Hold1
Underperform0
Sell0

12-month price target · 4 analysts

Average $48.45 (+810.7% upside)

Low: $15.15
Now: $5.32
High: $84.00

Upgrades and downgrades

The latest rating actions, newest first

CTSO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Mar 26, 2026	Maintains	Buy	$10.00	29%
D. Boral Capital	Jan 12, 2026	Maintains	Buy	$10.00	29%
D. Boral Capital	Dec 16, 2025	Maintains	Buy	$10.00	29%
D. Boral Capital	Nov 14, 2025	Maintains	Buy	$10.00	29%
HC Wainwright & Co.	Nov 14, 2025	Maintains	Neutral	$1.00 → $0.75	42%

The case for and against

Updated Jun 30, 2026

Bull case

CytoSorbents is a leader in blood purification technology for the treatment of life-threatening conditions, and their proprietary polymer beads technology has a wide range of applications, including removing blood thinners during cardiothoracic surgery and treating critical illnesses. With strong distributor sales in the U.S. and Canada, as well as royalty income from HemoDefend ABG/RBC in the U.S., the company has shown a track record of consistent growth. The company has also taken steps to strengthen its balance sheet and reach profitability through margin improvement and cost reduction initiatives. Continued growth in the German market is expected to further support the company's financial success.

Bear case

CytoSorbents is facing increasing competition in the blood purification market and has been struggling to gain market share for their products. Despite promising applications in the removal of blood thinners during surgeries and treatment of critical illnesses, the company has not been able to consistently generate significant revenue. Additionally, the significant increase in the company's selling, general, and administrative costs over the past year may have a negative impact on their bottom line.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.